Cardiovascular Diabetology最新文献

{"title":"Evaluative performance of triglyceride-glucose-frailty index versus surrogate insulin resistance indices for advanced cardiovascular-kidney-metabolic syndrome, cardiometabolic multimorbidity, and mortality: the role of estimated glomerular filtration rate.","authors":"Kang Liu, Jia-Yuan Zhang, Hui He, Yu-Qi Hu, Jia-Hui Lai, Jing-Yu Zhang, Bin Wang, Xia-Hong Lin","doi":"10.1186/s12933-026-03349-z","DOIUrl":"https://doi.org/10.1186/s12933-026-03349-z","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular-kidney-metabolic (CKM) syndrome and cardiometabolic multimorbidity (CMM) carry substantial mortality, yet whether a composite index integrating insulin resistance and frailty shows stronger associations with advanced CKM syndrome, CMM, and mortality than conventional metabolic markers remains unclear. This study evaluated the associations of the triglyceride-glucose-frailty index (TyG-FI) with CKM, CMM, and all-cause and cardiovascular mortality, and explored the role of baseline estimated glomerular filtration rate (eGFR).</p><p><strong>Methods: </strong>The analysis included 11,228 adults aged 20-79 years from the National Health and Nutrition Examination Survey 2001-2018. TyG-FI was calculated as the TyG index multiplied by the frailty index. Survey-weighted logistic and Cox proportional-hazards models were used to estimate odds and hazard ratios, with sequential adjustment for demographic, socioeconomic, and behavioral confounders. Restricted cubic splines examined non-linear relationships. Overall model performance was assessed using receiver operating characteristic curves with DeLong's test, time-dependent AUC, Harrell's C-index, calibration, and decision curve analysis. Exploratory mediation analyses quantified the proportion of mortality associations accounted for by baseline eGFR. Robustness was verified through multiple sensitivity and subgroup analyses.</p><p><strong>Results: </strong>Over a median follow-up of 90 months (1,220 all-cause and 379 cardiovascular deaths), higher TyG-FI quartiles were associated with graded decreases in survival. Compared with the lowest TyG-FI quartile, the highest quartile yielded markedly elevated odds for advanced CKM syndrome (OR = 4.57, 95% CI: 3.50-5.99) and CMM (OR = 5.09, 95% CI: 2.83-9.16), and higher hazard for all-cause (HR = 3.90, 95% CI: 2.96-5.13) and cardiovascular death (HR = 5.82, 95% CI: 3.38-10.03). Among participants with CMM, the relationship remained for all-cause death (HR = 2.69, 95% CI: 1.69-4.28). The dose-response patterns were non-linear for outcomes (P for non-linearity < 0.001). TyG-FI demonstrated higher discrimination than most surrogate insulin resistance indices, and lower baseline eGFR partly accounted for 16.45% to 26.74% of the associations with mortality. Sensitivity analyses corroborated the consistency of all findings.</p><p><strong>Conclusions: </strong>TyG-FI, which captures both metabolic dysfunction and physiological frailty, showed stronger associations with advanced CKM syndrome, prevalent CMM, and mortality than most surrogate insulin resistance indices. In exploratory analyses, lower baseline eGFR partly accounted for a proportion of the association with mortality. TyG-FI may offer a pragmatic tool for early mortality risk stratification in individuals with high cardiometabolic risk.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"25 1","pages":""},"PeriodicalIF":15.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Composite C-reactive protein-triglyceride-glucose adiposity indices and incident cardiovascular-liver-metabolic multimorbidity: a prospective cohort study.","authors":"Jing Chen, Zhonghua Sun, Jiajun Qiu, Zhongqing Zhou, Kaiqi Ma, Yongxin Liang, Chunqun Li, Shicong Liang","doi":"10.1186/s12933-026-03351-5","DOIUrl":"10.1186/s12933-026-03351-5","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The C-reactive protein-triglyceride-glucose index (CTI) is a comprehensive marker that reflects inflammation and insulin resistance. Cardiovascular-liver-metabolic (CLM) diseases caused by multiple factors may be related to insulin resistance, obesity, metabolism, etc. Our aim is to explore the association between the fat index derived from CTI and a newly identified surrogate-defined CLM multimorbidity (CLMM) phenotype, while also comparing the relative discriminatory performance of these indices and exploring potential biological domains.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;From the China Health and Retirement Longitudinal Study (CHARLS), a total of 6534 individuals with full baseline records were included in our analysis. Nine CTI-derived adiposity indices were calculated, including CTI, CTI-BMI, CTI-WC, CTI-WHtR, CTI-BRI, CTI-WWI, CTI-CVAI, CTI-ABSI, and CTI-CI. CVD was identified primarily from self-reported physician diagnoses, whereas MASLD was inferred using the lipid accumulation product (LAP) rather than imaging, histology, or clinical adjudication. Because the component conditions were ascertained using different methods and levels of diagnostic accuracy, CLMM was operationalized as a surrogate-defined composite phenotype rather than clinically confirmed CLMM. Associations as well as potential nonlinear relationships were examined using multivariable logistic regression, restricted cubic spline (RCS) modeling, and two-piece segmented regression analyses. Apparent discrimination and exploratory incremental model performance were quantified using receiver operating characteristic (ROC) curve analysis and reclassification measures, specifically the net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Subgroup and sensitivity analyses were performed to assess stability.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;During the approximately four-year follow-up interval, 406 participants (6.2%) met the criteria for the newly identified surrogate-defined CLMM phenotype. Most CTI-derived adiposity indicators were significantly associated with elevated odds of this phenotype, although CTI-ABSI and CTI-WWI showed null associations after full adjustment. In fully adjusted models, CTI-BMI and CTI-CVAI (Q4 OR 3.46 for CTI-BMI; Q4 OR 2.37 for CTI-CVAI) showed the strongest associations (both P &lt;0.001). RCS analyses further indicated significant nonlinear exposure-response relationships for all indices, except for CTI. CTI-BMI had the highest AUC among the evaluated CTI-derived indices (AUC = 0.638, 95% CI 0.611-0.664), although its absolute discriminatory ability was modest. However, CTI-BMI did not materially outperform BMI alone in a direct same-sample comparison (AUC = 0.638 vs 0.638; DeLong P = 0.924), and the IDI for CTI-BMI versus BMI was only 0.02%, despite a positive NRI. When CTI-BMI was added to the fully adjusted baseline model, the AUC increased only slightly from 0.617 to 0.627. Although ","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"25 1","pages":""},"PeriodicalIF":15.6,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13525692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Composite metabolic biomarkers for cardiovascular risk assessment in CKM syndrome.","authors":"Shaun Khanna, Francis J Ha, Nitesh Nerlekar","doi":"10.1186/s12933-026-03338-2","DOIUrl":"10.1186/s12933-026-03338-2","url":null,"abstract":"","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"25 1","pages":""},"PeriodicalIF":15.6,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13520190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148825205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clarifying the role of TyG-VLR in CKM risk characterization: Reply to \"Composite metabolic biomarkers for cardiovascular risk assessment in CKM syndrome\".","authors":"Ao-Men Lu, Hao-Jie Han, Qian Xu, Shuang-Ke Bai","doi":"10.1186/s12933-026-03337-3","DOIUrl":"10.1186/s12933-026-03337-3","url":null,"abstract":"","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"25 1","pages":""},"PeriodicalIF":15.6,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13520348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148825224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception.","authors":"Nizameddin Koca, Seyit Uyar, Yasin Şahintürk, Hamit Yıldız, Stefano Del Prato, RalphA DeFronzo","doi":"10.1186/s12933-026-03346-2","DOIUrl":"10.1186/s12933-026-03346-2","url":null,"abstract":"<p><p>The traditional glucose-centric paradigm of type 2 diabetes management is being superseded by growing evidence that certain agents, sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and pioglitazone, confer cardiovascular, renal, and hepatic benefits that extend well beyond glycemic control. Building on the previously proposed \"diabetes/disease-modifying drugs (DMDs)\" concept introduced through the SIMPLE framework, we propose a more mechanistically precise term: Disease-Modifying Anti-Diabetic Drugs (DMADDs). DMADDs are defined by four criteria: glucose-independent clinical benefit, durable organ-specific protection, mechanistic evidence of anti-inflammatory or anti-fibrotic activity, and sustained legacy effects or remission potential. Using these criteria, SGLT2i, GLP-1RA, and pioglitazone emerge as prototypical agents, while metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors, insulin, and sulfonylureas do not meet the full threshold. We explicitly explain why metformin and DPP-4 inhibitors are excluded as DMADDs, situate the DMADD framework within the heterogeneity of type 2 diabetes and against what non-pharmacological interventions can achieve, and state the limitations of the proposal. Recent evidence reinforces this framework: the SOUL trial established cardiovascular superiority for oral semaglutide, extending disease-modifying properties beyond injectable formulations, while Phase 3 TRIUMPH data position retatrutide as an emerging triple-agonist candidate awaiting cardiovascular outcome data. The 2026 American Diabetes Association Standards of Care now recommend SGLT2i and GLP-1RA independent of baseline glycated hemoglobin (HbA1c), an institutional shift that mirrors the disease-interception logic proposed here. We argue that adopting the DMADD framework could reorient diabetes therapeutics from glycemic normalization toward early disease interception, potentially preserving β-cell function and expanding the clinical horizon toward remission. This terminology offers a unifying scaffold for future trials, regulatory classification, and clinical guidelines, redefining therapeutic success in type 2 diabetes beyond glucose control alone.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"25 1","pages":""},"PeriodicalIF":15.6,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13520461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148825320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excess risk of cardiovascular disease and mortality after amputation in type 2 diabetes: a nationwide population study from the Swedish National Diabetes Register.","authors":"Karin Bergqvist, Henrik Imberg, Sara Hallström, Jens Michelsen, Hanna Liljebäck, Stefan Franzén, Anna Norhammar, Annika Rosengren, Marcus Lind","doi":"10.1186/s12933-026-03319-5","DOIUrl":"10.1186/s12933-026-03319-5","url":null,"abstract":"<p><strong>Background: </strong>Individuals with diabetes are prone to peripheral angiopathy and neuropathy, predisposing them to diabetic foot ulcers and, ultimately, lower-extremity amputation. The long-term cardiovascular impact of amputation in persons with type 2 diabetes remains insufficiently characterised. The aim of this study was to examine the extent to which lower-extremity amputation in individuals with type 2 diabetes is associated with an increased risk of cardiovascular disease and mortality compared to those with type 2 diabetes without amputation.</p><p><strong>Methods: </strong>This was an observational, population-based retrospective cohort study with data from the Swedish National Diabetes Register linked to the National Patient Register and the Cause of Death Register. All individuals with type 2 diabetes who underwent a major or minor lower-extremity amputation between 2006 and 2019 were identified and matched to four controls with type 2 diabetes but without previous amputation on age, sex, and calendar time. Adjusted hazard ratios (aHRs) for cardiovascular events and mortality were estimated using cause-specific Cox proportional hazards regression, accounting for demographic and clinical risk factors.</p><p><strong>Results: </strong>A total of 3,485 individuals with type 2 diabetes who had undergone amputation and 13,940 matched controls without previous amputation were included. Individuals undergoing amputation had a markedly increased risk of cardiovascular disease and mortality, with aHRs (95% CI) of 2.46 (2.31-2.61) for all-cause mortality, 2.43 (2.18-2.71) for cardiovascular mortality, 2.13 (1.92-2.36) for heart failure, 1.79 (1.55-2.08) for myocardial infarction, and 1.52 (1.31-1.76) for stroke. The hazard of all-cause mortality was more than threefold higher in the first year after amputation compared with matched controls and remained about 50% higher after five years.</p><p><strong>Conclusions: </strong>Lower-extremity amputation in individuals with type 2 diabetes is associated with a substantially increased risk of cardiovascular disease and mortality, independent of pre-existing cardiovascular disease and established risk factors. This underlines the need for intensive cardiovascular risk management both before and after amputation to improve long-term outcomes.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"25 1","pages":""},"PeriodicalIF":15.6,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13520145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148825335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Associations of cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose index with incident stroke in middle-aged and older Chinese adults: a longitudinal analysis based on CHARLS.","authors":"Yibo Yang, Aihua Liu","doi":"10.1186/s12933-026-03328-4","DOIUrl":"10.1186/s12933-026-03328-4","url":null,"abstract":"","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"25 1","pages":""},"PeriodicalIF":15.6,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13495241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A cardiometabolic perspective on post-exertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID.","authors":"Francisco Westermeier, Etheresia Pretorius, Eva Untersmayr, Romina Bertinat, Nuno Sepúlveda, Enrique Fisman","doi":"10.1186/s12933-026-03316-8","DOIUrl":"https://doi.org/10.1186/s12933-026-03316-8","url":null,"abstract":"<p><p>Post-exertional malaise (PEM), the defining feature of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), is increasingly recognized in individuals with Long COVID. Although traditionally viewed as symptom exacerbation and/or emergence of new symptoms following exertion, PEM may reflect disrupted coordination across interconnected physiological systems operating over distinct post-exertional timescales. Such disruption may result in altered post-exertional physiological trajectories that contribute to multisystem manifestations and potential cardiometabolic consequences. This perspective outlines a conceptual approach for investigating PEM through longitudinal assessment of post-exertional physiological trajectories while considering disease severity and underlying cardiometabolic health, including obesity and type 2 diabetes. Integrating these dimensions may help contextualize post-exertional responses, inform future longitudinal cardiometabolic profiling, facilitate patient stratification, and provide a framework for future mechanistic and interventional studies in ME/CFS and Long COVID.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"25 1","pages":""},"PeriodicalIF":15.6,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13495169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Associations of cumulative exposure and dynamic trajectories of the triglyceride-total cholesterol-body weight index with new-onset cardiometabolic multimorbidity in middle-aged and older Chinese adults: evidence from a nationwide prospective cohort study.","authors":"Xiao Chen, Chaochao Wang, Qi Huang, Yuan Luo, Zhe Wu, Jing Chen, Haibo Gong","doi":"10.1186/s12933-026-03321-x","DOIUrl":"10.1186/s12933-026-03321-x","url":null,"abstract":"","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"25 1","pages":""},"PeriodicalIF":15.6,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13471163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148720102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A three-metabolite microbiota-associated signature for early risk stratification of gestational diabetes mellitus.","authors":"Shuo Ma, Chen Zhang, Yuming Yao, Meiling Zhou, Ai Chen, Yaya Chen, Yinhao Chen, Jiwei Wang, Gulinaizhaer Abudushalamu, Shijie Cai, Fengfeng Zhao, Dawen Chen, Xiao Li, Yue Zheng, Juxiang Fan, Xun Gao, Yonghui Liu, Weimin Fan, Feng Zhu, Jin Yang, Miao Miao, Xiaobo Fan, Guoqiu Wu","doi":"10.1186/s12933-026-03278-x","DOIUrl":"10.1186/s12933-026-03278-x","url":null,"abstract":"<p><strong>Background: </strong>Gestational diabetes mellitus (GDM) is associated with adverse pregnancy outcomes and long-term metabolic and cardiovascular risk. However, oral glucose tolerance testing at 24-28 gestational weeks limits early risk stratification. Gut microbiota-associated metabolites may reflect early metabolic abnormalities, including those relevant to cardiometabolic health, but robust early-pregnancy biomarkers remain limited.</p><p><strong>Methods: </strong>We conducted a multicenter nested case-control and prospective study involving 2,693 pregnant women. Untargeted metabolomics and metagenomics were integrated to identify GDM-associated metabolites and gut microbial alterations. Three consistently dysregulated metabolites, 3-hydroxydecanoic acid, γ-Glu-Leu, and propionic acid, were quantified by targeted LC-MS/MS. Candidate algorithms were compared using repeated 10-fold cross-validation, and a final generalized linear model was externally and prospectively validated.</p><p><strong>Results: </strong>Women who later developed GDM showed an adverse early-pregnancy metabolic profile, including higher BMI, triglycerides, and platelet count. Untargeted metabolomics identified 14 persistently altered metabolites enriched in energy, oxidative stress, and amino acid metabolism pathways. Metagenomics revealed taxonomic restructuring and coordinated microbiota-metabolite associations. The three-metabolite model achieved AUCs of 0.838 (95% CI, 0.791-0.885) in training, 0.840 (95% CI, 0.769-0.911) in internal validation, 0.955 (95% CI, 0.925-0.985) and 0.917 (95% CI, 0.875-0.958) in two external cohorts, and 0.969 (95% CI, 0.937-1.000) in the prospective cohort.</p><p><strong>Conclusion: </strong>Early microbiota-associated metabolic dysregulation is detectable before routine GDM diagnosis. This compact three-metabolite panel may support early GDM risk stratification and provides metabolic evidence relevant to broader cardiometabolic risk assessment in pregnancy.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"25 1","pages":""},"PeriodicalIF":15.6,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13450031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148688431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}